Recombinant Anti-Csl x Anti-CD3 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-Csl specificity or anti-CD3 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Breast cancer; Glioma cancaer; Glioblastoma; Multiple myeloma (MM); Leukemia therapy.
scFv-based Bispecific Fragments
FuncS; Promising therapeutic agent
Breast cancer; Glioma cancaer; Glioblastoma; Multiple myeloma (MM); Leukemia
SUH; csl; AOS3; CBF1; KBF2; RBP-J; RBPJK; IGKJRB; RBPSUH; IGKJRB1; recombination signal binding protein for immunoglobulin kappa J region; RBPJ; Lag-1; Suppressor of hairless
CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email